Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer

Recruiting now

Conditions studied: Non Small Cell Lung Cancer

In brief

Although several clinical trials provide evidence for efficacy benefit for Checkpoint Inhibitors plus chemotherapy for lung cancer. However, there was rare evidence for clinical evidence in Hunan province.

Key facts

Study ID

NCT05059951

Run by

Hunan Province Tumor Hospital

People needed

15000

Starts

2021-10-03

Expected to finish

2028-03-01

Last updated by the study team

2024-06-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ≥18，Lung Cancer Confirmed by Histopathology
• Treated with Chemotherapy with or Without Checkpoint Inhibitors.
• ECOG 0 - 1.
• Predicted survival ≥ 12 weeks.
• Adequate bone marrow hematopoiesis and organ function
• Presence of measurable lesions according to RECIST 1.1.
• Subjects with stable brain metastases may be included in the study.

You may not qualify if…

• Patients did not match for the Inclusion Criteria.

Where it is running

• Hunan Cancer Hospital — Changsha, Hunan, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.